Eli Lilly & Co.'s pegilodecakin, the lead immuno-oncology asset from its $1.6bn acquisition of Armo BioSciences Inc. last year, is the latest drug to fail as a potential therapy for notoriously difficult-to-treat pancreatic cancer.
The US major has announced top-line results from its Phase III SEQUOIA trial evaluating pegilodecakin, plus the widely-used FOLFOX (folinic...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)